Morningside Venture Investments Ltd → Amylyx Pharmaceuticals, Inc. AMLX

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 25/100

Passive Schedule 13G filer baseline
Held by 1 tracked 13F institutional manager
Elevated short days-to-cover (9.9 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

2 transactions

2 buys · 0 sales · 0 awards/exercises

Issuer Cluster

2 13D/G filings on this issuer

1 other filing besides this one

Filer Track Record

7 filings by this filer

6 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 9.93

13,249,442 shares short · +4.6% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $4.05M

Point72 Asset Mgmt

Form 4 Insider Transactions · last 365d

Date	Insider	Role	Type	Shares	Price	Value
2026-08-18	FRATES JAMES M	officer	Award	22,807	—	—
2026-08-18	Klee Justin B.	director, officer	Award	60,039	—	—

Other 13D/G Filings on Amylyx Pharmaceuticals, Inc.

Filed	Form	Filer	Stake	Shares
2023-10-04	SC	Morningside Venture Investments Ltd	—	—	view →

Other Filings by Morningside Venture Investments Ltd

Filed	Form	Issuer	Stake	Shares
2025-01-16	SCHEDULE	Kezar Life Sciences, Inc. KZR	8.45%	616,502	view →
2023-10-04	SC	Amylyx Pharmaceuticals, Inc. AMLX	—	—	view →
2023-02-23	SC	LumiraDx Ltd	—	—	view →
2021-11-22	SC	Stealth BioTherapeutics Corp	—	—	view →
2021-02-16	SC	Kezar Life Sciences, Inc. KZR	—	—	view →
2020-06-16	SC	Kezar Life Sciences, Inc. KZR	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →